TABLE 2Calculation of prognostic risk scores using the Hasford and Sokal scores

Calculation using the Hasford score16Calculation using the Sokal score15
Relative riska
Low≤ 780< 0.8
Intermediate781–14800.8–1.2
High> 1480> 1.2
Age0.666 when age ≥ 50 years0.116 × (age − 43.4 years)
Spleenb0.042 × spleen0.0345 × (spleen − 7.51)
Platelet count (× 109/l)1.0956 when platelet count ≥1500 × 109/l0.188 × [(platelet count ÷ 700)2 − 0.563]
Blood myeloblasts (%)0.0584 × myeloblasts0.0887 × (myeloblasts − 2.10)
Blood basophils (%)0.20399 when basophils > 3%NA
Blood eosinophils (%)0.0413 × eosinophilsNA

NA, not applicable.

a

Relative risk for the Sokal calculation is expressed as the exponential of the total and the Hasford risk score is expressed as the total × 1000.

b

Centimetres below costal margin, maximum distance.

From: 1, Background

Cover of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.22.
Rogers G, Hoyle M, Thompson Coon J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.